NewAmsterdam PharmaNAMS
NAMS
About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Employees: 68
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
98% more capital invested
Capital invested by funds: $1.28B [Q3] → $2.53B (+$1.25B) [Q4]
60% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 8 (+3) [Q4]
35% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 31
30% more funds holding
Funds holding: 100 [Q3] → 130 (+30) [Q4]
8.73% more ownership
Funds ownership: 85.64% [Q3] → 94.37% (+8.73%) [Q4]
35% less call options, than puts
Call options by funds: $8.11M | Put options by funds: $12.6M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$42
120%
upside
Avg. target
$47
146%
upside
High target
$52
172%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger 50% 1-year accuracy 62 / 125 met price target | 120%upside $42 | Buy Reiterated | 8 Apr 2025 |
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target | 172%upside $52 | Sector Outperform Maintained | 27 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
18 hours ago
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers
Neutral
GlobeNewsWire
3 weeks ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 133,000 of NewAmsterdam's ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a virtual fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET.
Positive
Seeking Alpha
2 months ago
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib
New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to file for European approval in 2025, with ongoing trials potentially confirming additional cardiovascular benefits. Despite competition, obicetrapib's oral administration and lack of side effects position it favorably against injectable PCSK9 inhibitors.
Positive
Seeking Alpha
2 months ago
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution
NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures, obicetrapib's clean safety profile and efficacy position it well in the cardiovascular market. The PREVAIL trial is crucial for proving obicetrapib's ability to reduce major cardiovascular events, a key to regulatory approval and market adoption.
Neutral
GlobeNewsWire
2 months ago
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 --
Neutral
GlobeNewsWire
2 months ago
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
2 months ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 138,000 of NewAmsterdam's ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 months ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 58,000 of NewAmsterdam's ordinary shares to two non-executive new hires and a grant of inducement share options covering 170,800 of NewAmsterdam's ordinary shares to Maryellen McQuade, the Company's new Chief People Officer. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
4 months ago
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritten public offering of (i) 14,667,347 of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share, which includes the exercise in full of the underwriters' option to purchase an additional 2,550,000 Ordinary Shares, and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (such offering, the “Offering”). All of the securities sold in the Offering were sold by the Company.
Charts implemented using Lightweight Charts™